Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
P/B ratio for Spruce Biosciences, Inc. (SPRB)
P/B ratio as of 2023: 1.47
According to Spruce Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.47. At the end of 2022 the company had a P/B ratio of 0.38.
P/B ratio history for Spruce Biosciences, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.47 |
| 2022 | 0.38 |
| 2021 | 0.94 |
| 2020 | 3.78 |
| 2019 | -12.35 |
| 2018 | -4.67 |